Bioinformatics in Drug Discovery a Revi
Author(s) -
N. Siddharthan,
M. Raja Prabu,
B. Sivasankari
Publication year - 2016
Publication title -
international journal of research in arts and science
Language(s) - English
Resource type - Journals
ISSN - 2394-9759
DOI - 10.9756/ijras.8099
Subject(s) - drug discovery , drug , identification (biology) , drug development , computational biology , pharmacology , drug candidate , potency , clinical pharmacology , bioinformatics , medicine , biology , in vitro , genetics , botany
The drug discovery process was beginning in 19 th century by John Langley in 1905 when he proposed the theory of respective substances. Drug discovery is the step-by- step process by which new candidate drugs are discovered. Bioinformatics deals with the exponential growth and the development in primary and secondary databases like nucleic acid sequences, protein sequences and structures. Drugs are usually only developed when the particular drug target for those drugs' actions have been identified and studied. Drug target validation helps us to check the potential for failure in the clinical testing and approval phases. Drug discovery also involves several phases from target identification to preclinical development. The aim of this study is to produce lead compounds i.e., new analogs with improved potency. The study of the promising compound can be divided into two different stages - preclinical pharmacology and clinical pharmacology.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom